IBOV 166,376.43 ▼ 0.69% COLCAP 2,452.46 — — IPC MEX 68,629.46 ▼ 0.12% MERVAL 2,848,945 — — USD/BRL5.91▼ 0.70% USD/MXN19.14▲ 0.30% USD/CLP 1,022 — 0.00% USD/COP3,483▲ 3.77% USD/PEN3.45▲ 0.19% USD/ARS1,580▲ 0.93% USD/UYU40.61▲ 3.16% USD/PYG6,212▲ 2.34% USD/BOB11.64▲ 2.55% USD/DOP59.52▼ 0.80% USD/CRC441.73▲ 2.68% USD/GTQ7.64▲ 3.22% USD/HNL26.89▲ 3.31% USD/NIO36.62▼ 0.69% USD/VES913.46▼ 0.45% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.59▲ 2.60% USD/TTD6.70▲ 2.00% EUR/BRL6.52▲ 1.12% BRENT 89.95 ▼ 2.21% WTI 83.41 ▲ 0.24% IRON ORE 161.91 — — COPPER 5.49 ▼ 2.49% GOLD 3,515 ▼ 4.62% SILVER 41.07 ▼ 7.33% SOY 1,221 ▲ 1.10% CORN 448.75 ▲ 2.22% WHEAT 592.00 ▲ 2.38% COFFEE 273.35 ▼ 3.08% SUGAR 17.07 ▼ 0.52% ORANGE JUICE 129.25 ▼ 2.49% COTTON 79.30 ▲ 4.41% COCOA 5,150 ▲ 1.72% BEEF 227.70 ▲ 2.18% CATTLE 335.43 ▼ 0.78% LITHIUM 51.98 ▼ 4.33% PETR4 42.67 ▼ 1.16% VALE3 58.48 ▼ 0.88% ITUB4 40.07 ▼ 0.30% BBDC4 13.83 ▼ 1.78% ABEV3 16.08 ▲ 0.06% BBAS3 14.30 ▲ 1.27% B3SA3 14.28 ▼ 0.14% WEGE3 51.13 ▼ 0.49% PRIO3 60.20 ▼ 2.70% SUZB3 55.32 ▼ 0.50% RENT3 28.86 ▼ 2.00% AZZA3 14.63 ▼ 7.29% CSAN3 3.08 ▼ 1.60% RAIZ4 15.00 ▼ 10.71% PCAR3 3.23 ▲ 8.03% GMAT3 4.18 ▲ 3.21% PSSA3 43.96 ▼ 1.57% CVCB3 0.72 ▼ 7.69% POSI3 3.37 ▲ 6.31% SLCE3 17.53 ▼ 1.96% NATU3 4.48 ▼ 6.28% BRKM5 2.60 ▼ 1.14% RANI3 8.01 ▼ 0.74% IBOV 166,376.43 ▼ 0.69% COLCAP 2,452.46 — — IPC MEX 68,629.46 ▼ 0.12% MERVAL 2,848,945 — — USD/BRL 5.91 ▼ 0.70% USD/MXN 19.14 ▲ 0.30% USD/CLP 1,022 — 0.00% USD/COP 3,483 ▲ 3.77% USD/PEN 3.45 ▲ 0.19% USD/ARS 1,580 ▲ 0.93% USD/UYU 40.61 ▲ 3.16% USD/PYG 6,212 ▲ 2.34% USD/BOB 11.64 ▲ 2.55% USD/DOP 59.52 ▼ 0.80% USD/CRC 441.73 ▲ 2.68% USD/GTQ 7.64 ▲ 3.22% USD/HNL 26.89 ▲ 3.31% USD/NIO 36.62 ▼ 0.69% USD/VES 913.46 ▼ 0.45% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.59 ▲ 2.60% USD/TTD 6.70 ▲ 2.00% EUR/BRL 6.52 ▲ 1.12% BRENT 89.95 ▼ 2.21% WTI 83.41 ▲ 0.24% IRON ORE 161.91 — — COPPER 5.49 ▼ 2.49% GOLD 3,515 ▼ 4.62% SILVER 41.07 ▼ 7.33% SOY 1,221 ▲ 1.10% CORN 448.75 ▲ 2.22% WHEAT 592.00 ▲ 2.38% COFFEE 273.35 ▼ 3.08% SUGAR 17.07 ▼ 0.52% ORANGE JUICE 129.25 ▼ 2.49% COTTON 79.30 ▲ 4.41% COCOA 5,150 ▲ 1.72% BEEF 227.70 ▲ 2.18% CATTLE 335.43 ▼ 0.78% LITHIUM 51.98 ▼ 4.33% PETR4 42.67 ▼ 1.16% VALE3 58.48 ▼ 0.88% ITUB4 40.07 ▼ 0.30% BBDC4 13.83 ▼ 1.78% ABEV3 16.08 ▲ 0.06% BBAS3 14.30 ▲ 1.27% B3SA3 14.28 ▼ 0.14% WEGE3 51.13 ▼ 0.49% PRIO3 60.20 ▼ 2.70% SUZB3 55.32 ▼ 0.50% RENT3 28.86 ▼ 2.00% AZZA3 14.63 ▼ 7.29% CSAN3 3.08 ▼ 1.60% RAIZ4 15.00 ▼ 10.71% PCAR3 3.23 ▲ 8.03% GMAT3 4.18 ▲ 3.21% PSSA3 43.96 ▼ 1.57% CVCB3 0.72 ▼ 7.69% POSI3 3.37 ▲ 6.31% SLCE3 17.53 ▼ 1.96% NATU3 4.48 ▼ 6.28% BRKM5 2.60 ▼ 1.14% RANI3 8.01 ▼ 0.74%
since 2009
Saturday, November 21, 2026

Brazil Life & Society

Brazilian Health Watchdog Wants to Allow Medical Marijuana Plantations

By · · 2 min read
Anvisa's members expect that the measure will encourage a new sector for the production of cannabis-based drugs in Brazil.
Anvisa’s members expect that the measure will encourage a new sector for the production of cannabis-based drugs in Brazil.

By Richard Mann

RIO DE JANEIRO, BRAZIL – The measures are part of a proposal submitted by Anvisa (National Health Surveillance Agency) on Tuesday, June 11th, to try to liberalize the cultivation of cannabis in Brazil, with a focus on research and the production of medicinal products. The proposal will now be submitted for public consultation for 60 days.

RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

Currently, marijuana planting is forbidden in Brazil. Since 2006, however, Law 11.343 provides for the possibility for the federal government to authorize planting “for medicinal and scientific purposes at a predefined location and within a predefined period and under supervision”.

The proposal for rules for the planting of cannabis thus represents a first regulatory attempt by the agency, which should increase the prospects for medicinal use of marijuana in Brazil.

For this purpose, each company is required to provide a safety plan with measures to prevent deviations. The approval will also be conditional upon a criminal background check of company officers and directors. Even if Anvisa approves, the Federal Police must be consulted.

If approved, planting must comply with specific rules and be carried out in closed and unidentified places, sealed by a double door with a locking system and protected by alarms and security systems. Access should be monitored employing biometrics.

The plants can be grown for research and for medicines to be produced by the company itself or sold to research institutions, manufacturers of pharmaceutical products, and laboratories that produce medication. Sale to individuals and compounding pharmacies will be prohibited.

Despite restrictions, Anvisa’s members expect that the measure will encourage a new sector for the production of cannabis-based drugs in Brazil, which may reduce the price of these products. Anvisa has been authorizing orders for the import of cannabidiol-based oils and medicines since 2015.

However, as they are produced abroad, there is no production quality control, and costs are high. In some instances, a three-month treatment costs approximately R$2,000 (US$500), which has led to an increase in legal actions demanding that health plans and the national health system supply the products.

Despite the apparent consensus among Anvisa’s directors, the proposal could still create friction with the government, which has adopted a stricter stance over drugs.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.